Understanding the high infectious disease mortality among patients receiving Hemodialysis: Potential risk of concurrently low cathelicidin and gelsolin levels

Clinical Infectious Diseases

Volumn 49, Issue 1, 2009, Pages 163-164

  Dinubile, Mark J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHELICIDIN; GELSOLIN;

HEMODIALYSIS; HUMAN; INFECTION; INFECTION SENSITIVITY; INNATE IMMUNITY; INTRAVENOUS CATHETER; KIDNEY FAILURE; LETTER; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SECRETION; VASCULAR ACCESS;

ANTIMICROBIAL CATIONIC PEPTIDES; COMMUNICABLE DISEASES; GELSOLIN; HUMANS; RENAL DIALYSIS;

EID: 66949120999     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/599617     Document Type: Letter

References (22)

1. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349:446-56.
2. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-13.
3. Isakova T, Gutierrez OM, Yuchiao Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009; 20:388-96.
4. Gombart AF, Bhan I, Borregaard N, et al. Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing he- modialysis. Clin Infect Dis 2009;48:418-24.
5. Bucki R, Byfield FJ, Janmey PA. Release of the antimicrobial peptide LL-37 from DNA/F-ac- tin bundles in cystic fibrosis sputum. Eur Respir J 2007; 29:624-32.
6. Weiner DJ, Bucki R, Janmey PA. The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin. Am J Respir Cell Mol Biol 2003;28:738-45.
7. Lee WM, Galbraith RM. The extracellular ac- tin-scavenger system and actin toxicity. N Engl JMed 1992;326:1335-41.
8. Lee PS, Patel SR, Christiani DC, Bajwa E, Stos- sel TP, Waxman AB. Plasma gelsolin depletion and circulating actin in sepsis: a pilot study. PLoS ONE 2008; 3:e3712.
9. Lind SE, Smith DB, Janmey PA, Stossel TP. Role of plasma gelsolin and the vitamin D-binding protein in clearing actin from the circulation. J Clin Invest 1986; 78:736-42.
10. Nijnik A, Hancock RE. The roles of catheli- cidin LL-37 in immune defenses and novel clinical applications. Curr Opin Hematol 2009; 16:41-7.
11. Nagaoka I, Tamura H, Hirata M. An antimicrobial cathelicidin peptide, human CAP18/LL-37, suppresses neutrophil apopto- sis via the activation of formyl-peptide receptor-like 1 and P2X7. J Immunol 2006; 176:3044-52.
12. Bucki R, Georges PC, Espinassous Q, et al. Inactivation of endotoxin by human plasma gelsolin. Biochemistry 2005; 44:9590-7.
13. Bucki R, Byfield FJ, Kulakowska A, et al. Extracellular gelsolin binds lipoteichoic acid and modulates cellular response to proinflamma- tory bacterial wall components. J Immunol 2008; 181:4936-44.
14. Osborn TM, Dahlgren C, Hartwig JH, Stossel TP. Modifications of cellular responses to ly- sophosphatidic acid and platelet activating factor by plasma gelsolin. Am J Physiol Cell Physiol 2007; 292:C1323-30.
15. Mounzer KC, Moncure M, Smith YR, Di- Nubile MJ. Relationship of admission plasma gelsolin levels to clinical outcomes in patients after major trauma. Am J Respir Crit Care Med 1999; 160:1673-81.
16. Suhler E, Lin W, Yin HL, Lee WN. Decreased plasma gelsolin concentration in acute liver failure, myocardial infarction, septic shock, and myonecrosis. Crit Care Med 1997;25:594-8.
17. Lee PS, Waxman AB, Magnuson T, et al. Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med 2007; 35:849-55.
18. Lee PS, Sampath K, Karumanchi A, et al. Plasma gelsolin and circulating actin correlate with hemodialysis mortality. J Am Soc Ne- phrol 2009;20:1140-8.
19. Kovesdy CP, Kalantar-Zadeh K. Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int 2008;73:1355-63.
20. Kalantar-Zadeh K, Brennan MI, Hazen SL. Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Am J Kidney Dis 2006; 48:59-68.
21. Kovesdy CP, Kalantar-Zadeh K. Why is protein-energy wasting associated with mortality in chronic kidney disease? Semin Nephrol 2009; 29:3-14.
22. DiNubile MJ. Plasma gelsolin: in search ofits raison d'etre: focus on "modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin". Am J Physiol Cell Physiol 2007; 292:C1240-2.